Percheron completes Phase 2B trial recruitmentFormerly called...

Percheron completes Phase 2B trial recruitment

Formerly called Antisense Therapeutics Percheron Therapeutics (ASXER) this week announced successful completion of recruitment to its ongoing international Phase 2b study of ATL1102 in the treatment of Duchenne muscular dystrophy (DMD).

Mid last year PER kicked off recruitment to the international phase 2b randomised controlled trial in the treatment of non-ambulant boys with DMD.

The study is now fully enrolled, with 48 boys randomised to the study across 16 hospitals in five countries.

The primary endpoint of the study is the change in PUL2.0 score at six months with data expected in December 2024, consistent with prior guidance.

“This is potentially a company making catalyst,” Wilkie says.

“Clear catalysts like this we see generally begin to trade up well into these clearly defined readouts.”